AgomAb Therapeutics AGMB Estimates

NASDAQ AGMB
$9.07 +0.35 (+3.95%)
As of: Oct 21, 2026 · 11:36 AM EDT
Analyst Estimates

AgomAb Therapeutics NV Annual Revenue Estimates

Periods 5
Next Period 2026
Consensus 448,404.26

Analysts expect AgomAb Therapeutics NV to report revenue of 448,404.26 for 2026, against a range of 421,574.44 to 475,234.08. The most recent reported year, 2025, came in at 0.00, a 100.0% miss against the 684,665.23 consensus.

Metric 20252026202720282029
Reported (Actual) 0.00--
High Estimate 746,378.90475,234.08602,839.64
Low Estimate 622,951.56421,574.44504,578.44
Consensus Estimate 684,665.23448,404.26553,709.04
Analyst Estimates

AgomAb Therapeutics NV Annual Earnings Per Share (EPS) Estimates

Periods 5
Next Period 2026
Consensus -1.86

Analysts expect AgomAb Therapeutics NV to report earnings per share of -1.86 for 2026, against a range of -1.92 to -1.80. The most recent reported year, 2025, came in at -168.21 , in line with the -2.18 consensus.

Metric 20252026202720282029
Reported (Actual) -168.21--
High Estimate -2.05-1.80-2.01
Low Estimate -2.31-1.92-2.25
Consensus Estimate -2.18-1.86-2.13

AgomAb Therapeutics NV Estimates API

Pull Wall Street consensus for AgomAb Therapeutics NV (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/estimates?ticker=AGMB&mode=revenue&api_key=YOUR_API_KEY